Wilbur D Scott
Department of Radiation Oncology, University of Washington, Seattle, Washington 98105, USA.
Curr Radiopharm. 2011 Jul;4(3):214-47. doi: 10.2174/1874471011104030214.
A review of chemical and radiochemical factors that must be considered when radiolabeling targeting agents with radionuclides is presented. The review discusses factors that are important in choice of radionuclide and choice of chelation or bonding reagents to use in the development of an α-emitting radiopharmaceutical. Chemical parameters, such as physical properties and pendant groups for radiolabeling, are reviewed. A major portion of the review outlines the development of chelates and labeling conditions for radiometals, and application of these reagents/conditions to radiometals. Acyclic and macrocyclic chelates containing amine and carboxylic acid coordination groups are highlighted, with examples of bifunctional chelates for biomolecule conjugation. Information is presented on over 60 radiometal-binding chelates. 211At radiolabeling is separated from that of radiometals, and the various reagents used for radiolabeling have been reviewed. Although not all 211At-labeling reagents are reviewed (due to another recent review), nearly 50 reagents studied in the development of pendant groups for labeling with 211At are described. The review also discusses how therapeutic doses of α-emitting radiopharmaceuticals can be affected by the radionuclide used and how radiation damage to the radiopharmaceutical can be minimized.
本文综述了用放射性核素对靶向剂进行放射性标记时必须考虑的化学和放射化学因素。该综述讨论了在选择放射性核素以及在开发发射α粒子的放射性药物时选择螯合或键合试剂方面重要的因素。对化学参数进行了综述,如放射性标记的物理性质和侧链基团。综述的主要部分概述了放射性金属螯合物的开发和标记条件,以及这些试剂/条件在放射性金属中的应用。重点介绍了含有胺和羧酸配位基团的无环和大环螯合物,并举例说明了用于生物分子偶联的双功能螯合物。文中介绍了60多种放射性金属结合螯合物的信息。211At放射性标记与放射性金属的标记分开论述,并对用于放射性标记的各种试剂进行了综述。虽然并非所有211At标记试剂都进行了综述(因为最近有另一篇综述),但描述了在开发用于211At标记的侧链基团时研究的近50种试剂。该综述还讨论了发射α粒子的放射性药物的治疗剂量如何受到所用放射性核素的影响,以及如何将对放射性药物的辐射损伤降至最低。